Search clinical trials for: Candesartan 16mg

Total 1170 results

HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

Essential Hypertension

Korea, Republic of
HK inno.N Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy

Essential Hypertension

Korea, Republic of
Shin Poong Pharmaceutical Co. Ltd.

Completed

Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
HK inno.N Corporation

Unknown

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

Essential Hypertension

Korea, Republic of
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers

Healthy Volunteer

China
HanAll BioPharma Co., Ltd.

Unknown

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

Hypertension
Chong Kun Dang Pharmaceutical

Unknown

A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

Essential Hypertension

Korea, Republic of
AstraZeneca

Completed

Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

Primary Hypertension

Romania
EnnovaBio Australia Pharmaceuticals Pty Ltd

Completed

A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects

Healthy

Australia
Chong Kun Dang Pharmaceutical

Completed

CKD-330 Drug-Drug Interaction Study (Candesartan) (CKD-330(C))

Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

Hypertension

Korea, Republic of
Bayer

Withdrawn

Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

Hypertension

Italy
Shin Poong Pharmaceutical Co. Ltd.

Completed

Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg

Healthy

Korea, Republic of
HK inno.N Corporation

Unknown

Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate (CCA)

Healthy
Chong Kun Dang Pharmaceutical

Completed

CKD-330 Drug-Drug Interaction Study (Amlodipine) (CKD-330(A))

Hypertension

Korea, Republic of
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Rheumatoid Arthritis

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-20094 in T2DM Participants

Type 2 Diabetes

China
Linda Van Eldik
National Institute on Aging (NIA); Duke Clinical Research Institute

Completed

MW151-101: First-in-human Study of MW151

Drug Toxicity

United States
AstraZeneca

Completed

ARIA (Atacand Renoprotection In NephropAthy Pt.) (PCR)

Non-diabetic Nephropathy With Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

Hypertension

India
Mitsubishi Tanabe Pharma America Inc.

Completed

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Menopause Hot Flashes

United States
Jiangsu Nhwa Pharmaceutical Co., Ltd.

Recruiting

A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese Subjects

Schizophrenia

China
University of Edinburgh
NHS Lothian

Completed

Cardiovascular Effects of Apelin In Healthy Volunteers

Healthy

United Kingdom
GlaxoSmithKline

Completed

Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions

Hypertension

India
GlaxoSmithKline

Completed

Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions

Cardiovascular Disease

India
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Not yet recruiting

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
St. Olavs Hospital
Ullevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaborators

Active, not recruiting

Candesartan for Migraine Prevention: (CandMig-3)

Migraine

Norway, Estonia
Takeda

Completed

Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"

Hypertension
Huazhong University of Science and Technology

Unknown

Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

Hypertension

China
AstraZeneca
Takeda

Completed

Diabetic Retinopathy Candesartan Trials (DIRECT)

Type 1 Diabetes

Denmark, Australia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
AstraZeneca

Completed

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

Proteinuria

Canada
HK inno.N Corporation

Unknown

Bioequivalence Study of CJ-30059 (CCA)

Healthy Volunteers

Korea, Republic of
Herlev Hospital

Unknown

Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease

Cardiovascular Diseases | Kidney Failure, Chronic

Denmark
AstraZeneca

Completed

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age

Hypertension

United States, France, Italy, United Kingdom, Germany, Poland, Ukraine, Belgium, Puerto Rico, Denmark
Takeda

Completed

Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」

Hypertension

Japan
Ullevaal University Hospital
Takeda; AstraZeneca; Southern-Eastern Norway Health Authorities RHF

Completed

Scandinavian Candesartan Acute Stroke Trial (SCAST)

Stroke

Norway
Mayo Clinic

Completed

Angiotensin-II Blockade in Mitral Regurgitation

Mitral Regurgitation

United States
Chong Kun Dang Pharmaceutical

Completed

Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B

Hypertension
AstraZeneca

Completed

Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) (HIP)

Hypertension

France, Germany, Poland, Ukraine, Belgium, Italy
EMS

Withdrawn

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Essential Arterial Hypertension
AstraZeneca

Completed

Atacand (Candesartan) Real Life Study (Real Life)

Hypertension

Sweden
Chong Kun Dang Pharmaceutical

Completed

Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A

Hypertension
GlaxoSmithKline

Completed

A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323

Hypertension

India
Kyoto Prefectural University of Medicine

Terminated

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients (KCPS)

Myocardial Ischemia | Hypertension | Angina Pectoris | Acute Coronary Syndrome | Acute Myocardial Infarction

Japan
Norwegian University of Science and Technology
AstraZeneca

Completed

Prophylactic Treatment of Episodic Cluster Headache

Cluster Headache

Norway
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Hypertension
University of Sydney
The George Institute for Global Health, India

Terminated

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 (CLARITY 2)

COVID-19 | SARS-CoV2 Infection

India
The Alfred

Completed

Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone

Heart Failure | Healthy

Australia
Kyorin University
Ministry of Health, Labour and Welfare, Japan

Unknown

CCB Safety Study in Treatment of Hypertension of ADPKD

Kidney, Polycystic, Autosomal Dominant

Japan

3

Subscribe